The recommendations for MIS-C focus on general guidance, diagnostic evaluation and therapy options, as well as comparing and contrasting the features of MIS-C and Kawasaki disease.
Search results for: pediatric rheumatology
Case Report: Which Vasculitis Is It?
A 13-year-old, adopted girl of unknown ancestry with social anxiety, selective mutism and Takayasu arteritis presented for evaluation of severe, painful, gingival hyperplasia, which limited her oral intake and resulted in weight loss. The young patient was diagnosed with Takayasu arteritis at age 8, when she presented with a persistently elevated erythrocyte sedimentation rate (ESR),…
Patient Sexual Orientation & Gender Identity: Do You Need to Know?—Ethics Forum
A 17-year-old girl presents to the pediatric rheumatology clinic for follow-up of recently diagnosed systemic lupus erythematosus (SLE) characterized by class IV lupus nephritis, photosensitive rash and antiphospholid antibody positivity. She is currently being treated with prednisone, mycophenolate mofetil, and hydroxychloroquine. She is accompanied by her mother, who has been very involved in the patient’s…
New Study Sheds Light on Deficiency of Adenosine Deaminase 2 (DADA2)
Since it was first described, the spectrum of disease caused by deficiency of adenosine deaminase 2 (DADA2) has been broadening. Features described include systemic vascular and inflammatory features and recurrent stroke, which overlap with childhood-onset polyarteritis nodosa (PAN). Previous data show that DADA2 has extensive genotypic and phenotypic variation.1 Results from a recently published study…
JIA & the Temporomandibular Joint: Diagnostic Challenges & Treatment Options
Juvenile idiopathic arthritis (JIA) can affect all joints, including the temporomandibular joints (TMJs). For a long time, the TMJ was a “forgotten” joint in pediatric rheumatology, although Sir Frederick Still did comment on a small mandible in his first case series on juvenile arthritis in 1897. In recent years, more attention has been given to…
New Options Emerge for Treating Macrophage Activation Syndrome
ATLANTA—Macrophage activation syndrome (MAS), a subset of hemophagocytic lymphohistiocytosis (HLH) disease, can be a fatal result of rheumatic disease. But there’s good news: New therapeutic options for refractory MAS targeting individual cytokines are emerging. At the 2019 ACR/ARP Annual Meeting, possible therapeutic options were presented during a pediatric-focused clinical and translational research track, Therapeutic Approaches…
Don’t Forget the Host: COVID-19 Cytokine Storm
The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.
Tips for Exploring Tough Topics with Teens with Rheumatic Disease
ATLANTA—Managing teenage patients may present challenges for pediatric rheumatologists and rheumatology professionals not only because of their often complex, rare conditions, but because teenagers are, well, teenagers. Teens may experiment with sexual intercourse, alcohol use, tobacco or vaping e-cigarettes to fit in with their peers, even if these habits have serious health consequences, according to…
New ACR/ARP Committee Members Are Ready to Work
Volunteering is a great way to give back and can be truly meaningful. Myriad worthwhile causes exist, so it can be hard to choose among them, but donating time to ACR and ARP committees helps promote rheumatology practice and brings awareness to rheumatic diseases. The College relies on volunteers to help achieve strategic priorities, promote…
ACR Advocacy: 2019 Year in Review
As a new year begins, Government Affairs Committee chair Blair Solow, MD, takes stock of ACR advocacy wins in 2019 and issues to watch in 2020.
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 95
- Next Page »